69460 Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices 

Drug Schedule 

5-Methoxy-N,N-diisopropyltryptamine (7439) .............................................................................................................................................. I 

N-Benzylpiperazine (7493) .......................................................................................................................................................................... I 

Etorphine (except HCl) (9056) .................................................................................................................................................................... I 

Heroin (9200) ............................................................................................................................................................................................... I 

Morphine-N-oxide (9307) ............................................................................................................................................................................. I 

Normorphine (9313) .................................................................................................................................................................................... I 

Pholcodine (9314) ....................................................................................................................................................................................... I 

Dextromoramide (9613) ............................................................................................................................................................................... I 

Dipipanone (9622) ....................................................................................................................................................................................... I 

Racemoramide (9645) ................................................................................................................................................................................. I 

Trimeperidine (9646) ................................................................................................................................................................................... I 

Tilidine (9750) .............................................................................................................................................................................................. I 

Amphetamine (1100) ................................................................................................................................................................................... II 

Methamphetamine (1105) ........................................................................................................................................................................... II 

Methylphenidate (1724) ............................................................................................................................................................................... II 

Amobarbital (2125) ...................................................................................................................................................................................... II 

Pentobarbital (2270) .................................................................................................................................................................................... II 

Secobarbital (2315) ..................................................................................................................................................................................... II 

Phencyclidine (7471) ................................................................................................................................................................................... II 

Phenylacetone (8501) ................................................................................................................................................................................. II 

Cocaine (9041) ............................................................................................................................................................................................ II 

Codeine (9050) ............................................................................................................................................................................................ II 

Dihydrocodeine (9120) ................................................................................................................................................................................ II 

Oxycodone (9143) ....................................................................................................................................................................................... II 

Hydromorphone (9150) ............................................................................................................................................................................... II 

Benzoylecgonine (9180) .............................................................................................................................................................................. II 

Ethylmorphine (9190) .................................................................................................................................................................................. II 

Meperidine (9230) ....................................................................................................................................................................................... II 

Methadone (9250) ....................................................................................................................................................................................... II 

Dextropropoxyphene, bulk (non-dosage forms) (9273) .............................................................................................................................. II 

Morphine (9300) .......................................................................................................................................................................................... II 

Oripavine (9330) .......................................................................................................................................................................................... II 

Thebaine (9333) .......................................................................................................................................................................................... II 

Levo-alphacetylmethadol (9648) ................................................................................................................................................................. II 

Oxymorphone (9652) ................................................................................................................................................................................... II 

Poppy Straw Concentrate (9670) ................................................................................................................................................................ II 

Fentanyl (9801).

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards. 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import crude opium, 

poppy straw, concentrate of poppy 

straw, and coca leaves. As explained in 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417 (2007), comments and requests 

for hearings on applications to import 

narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act [(21 U.S.C. 952 

(a)(2)(B)] may, in the circumstances set 

forth in 21 U.S.C. 958(i), file comments 

or objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR § 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 13, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28519 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

September 14, 2010, GE Healthcare, 

3350 North Ridge Avenue, Arlington 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices 69461 

Heights, Illinois 60004–1412, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Cocaine 

(9041), a basic class of controlled 

substance listed in schedule II. 

The company plans to import small 

quantities of ioflupane, in the form of 

three separate analogues of Cocaine, to 

validate production and quality control 

systems, for a reference standard, and 

for producing material for a future 

investigational new drug (IND) 

submission. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 13, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28529 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on June 

28, 2010, Wildlife Laboratories, 1401 

Duff Drive, Suite 400, Fort Collins, 

Colorado 80524, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Etorphine Hydrochloride 

(9059), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance for sale to its 

customer. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 13, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28526 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 17, 2010, and 

published in the Federal Register on 

June 28, 2010 (75 FR 36684), Cerilliant 

Corporation, 811 Paloma Drive, Suite A, 

Round Rock, Texas 78665–2402, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the basic 

classes of controlled substances listed in 

schedule I: 

Drug Schedule 

Racemoramide (9645) .................. I 

Tilidine (9750) ............................... I 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Cerilliant Corporation to import the 

basic classes of controlled substances is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Cerilliant Corporation 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: November 1, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–28523 Filed 11–10–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated August 13, 2010, and 

published in the Federal Register on 

mstockstill on DSKH9S0YB1PROD with NOTICES